



**LUPIN**

December 13, 2024

**National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
Mumbai - 400 051

**Symbol: LUPIN**

**BSE Limited**

P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
Mumbai - 400 001

**Scrip Code: Equity - 500257**

**Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').**

***Dear Sir/Madam,***

We are pleased to enclose a Press Release as regards acquisition of anti-diabetes trademarks GIBTULIO<sup>®</sup>, GIBTULIO MET<sup>®</sup> and AJADUO<sup>®</sup> from Boehringer Ingelheim International GmbH to strengthen the Company's diabetes portfolio in the Country.

The same is for your information and dissemination.

Thanking you,

**For LUPIN LIMITED**

**AMIT KUMAR GUPTA  
COMPANY SECRETARY & COMPLIANCE OFFICER  
(ACS -15754)**

**Encl: a/a.**

LUPIN LIMITED

Registered Office: 3<sup>rd</sup> Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

[www.lupin.com](http://www.lupin.com)

## Lupin Acquires 3 Trademarks from Boehringer Ingelheim to Strengthen Diabetes Portfolio

**GIBTULIO<sup>®</sup>, GIBTULIO MET<sup>®</sup> and AJADUO<sup>®</sup> are key components for Diabetes Treatment**

**Mumbai, December 13, 2024:** Global pharma major Lupin Limited (Lupin) announced today the acquisition of anti-diabetes trademarks GIBTULIO<sup>®</sup>, GIBTULIO MET<sup>®</sup> and AJADUO<sup>®</sup> from Boehringer Ingelheim International GmbH (Boehringer Ingelheim), to strengthen its diabetes portfolio in the country. As per the terms of the agreement, the trademark rights for these brands will be transferred to Lupin by March next year. Lupin has been marketing GIBTULIO<sup>®</sup> and GIBTULIO MET<sup>®</sup> since 2016, and AJADUO<sup>®</sup> since 2018 in the Indian market through existing co-marketing agreements with Boehringer Ingelheim India.

GIBTULIO<sup>®</sup> (empagliflozin), GIBTULIO MET<sup>®</sup> (empagliflozin + metformin) and AJADUO<sup>®</sup> (empagliflozin + linagliptin) belong to a novel class of oral anti-diabetic drug, sodium glucose co-transporter-2 (SGLT-2) inhibitor (and combinations). These are indicated to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. Empagliflozin is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes, and the risk of cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease.

An estimated 80 million<sup>1</sup> people above the age of 18 years have diabetes in India, in addition to 25 million<sup>2</sup> that are pre-diabetic. Awareness of diabetes is low with more than 50% of people unaware of their diabetic status, leading to multiple health complications, if not detected and treated early. Adults with diabetes have an increased risk of heart attack and stroke<sup>2</sup>.

“Lupin has always been at the forefront of providing best-in-class quality healthcare solutions to patients. This acquisition is a key step in strengthening our diabetes portfolio and reaffirms our commitment to delivering innovative and cost-effective medications for patients across India,” said **Nilesh Gupta, Managing Director, Lupin.**

Commenting on the acquisition, **Rajeev Sibal, President – India Region Formulations, Lupin** said, “The increasing prevalence of diabetes and related lifestyle diseases calls for greater thrust on diabetes treatment and management, as well as accessibility of medicines for patients. This acquisition enables us to deliver effective and affordable treatment options to millions across India.”

### About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

To know more, visit [www.lupin.com](http://www.lupin.com) or follow us on LinkedIn <https://www.linkedin.com/company/lupin>

For further information or queries please contact:

**Rajalakshmi Azariah**

**Vice President & Global Head – Corporate Communications, Lupin**

[rajalakshmiазariah@lupin.com](mailto:rajalakshmiазariah@lupin.com)

**References:**

<sup>1</sup> <https://diabetesatlas.org/data/en/country/93/in.html>

<sup>2</sup> <https://www.who.int/india/health-topics/diabetes#>